Table 3. Baseline characteristics stratified by patients who survived (or were lost to follow-up) for at least 1 year vs. those who did not.
| Characteristic | Total, (N=606) | Survived at least 1 year (or more), >1 year, (N=263) | Survived less than 1 year, <1 year, (N=343) | P-value |
|---|---|---|---|---|
| Gender | 0.932 | |||
| Female | 233 (38.4) | 100 (38.0) | 133 (38.8) | |
| Male | 373 (61.6) | 163 (62.0) | 210 (61.2) | |
| ECOG | 0.117 | |||
| 0 | 168 (65.4) | 77 (70.0) | 91 (61.9) | |
| 1 | 72 (28.0) | 29 (26.4) | 43 (29.3) | |
| 2 | 14 (5.4) | 4 (3.6) | 10 (6.8) | |
| 3 | 3 (1.2) | 0 | 3 (2.0) | |
| Ascites | 0.005 | |||
| No | 563 (95.3) | 252 (98.1) | 311 (93.1) | |
| Yes (controlled) | 5 (0.8) | 2 (0.8) | 3 (0.9) | |
| Yes (uncontrolled) | 23 (3.9) | 3 (1.2) | 20 (6.0) | |
| Extrahepatic metastases | <0.001 | |||
| No | 393 (64.9) | 199 (75.7) | 194 (56.6) | |
| Yes | 213 (35.1) | 64 (24.3) | 149 (43.4) | |
| Tumor/target liver involvement | <0.001 | |||
| <25% | 388 (69.5) | 205 (83.0) | 183 (58.8) | |
| 25%–50% | 148 (26.5) | 38 (15.4) | 110 (35.4) | |
| >50% | 22 (3.9) | 4 (1.6) | 18 (5.8) | |
| Prior chemotherapy lines | <0.001 | |||
| 0 (RE 1st line) | 35 (6.0) | 20 (7.9) | 15 (4.5) | |
| 1 (RE 2nd line) | 206 (35.3) | 109 (43.3) | 97 (29.3) | |
| 2 (RE 3rd line) | 184 (31.6) | 71 (28.2) | 113 (34.1) | |
| 3+ (RE 4th+ line) | 158 (27.1) | 52 (20.6) | 106 (32.0) | |
| Lung shunt | 0.014 | |||
| ≤10% | 526 (88.3) | 238 (91.9) | 288 (85.5) | |
| >10% | 70 (11.7) | 21 (8.1) | 49 (14.5) | |
| Albumin, CTC grade | <0.001 | |||
| 0 | 392 (66.3) | 208 (80.3) | 184 (55.4) | |
| 1+ | 199 (33.7) | 51 (19.7) | 148 (44.6) | |
| Alkaline phosphatase, CTC grade | <0.001 | |||
| 0 | 241 (40.7) | 154 (59.7) | 87 (26.0) | |
| 1+ | 351 (59.3) | 104 (40.3) | 247 (74.0) | |
| Aspartate amino-transferase, CTC grade | <0.001 | |||
| 0 | 296 (50.2) | 170 (65.9) | 126 (38.0) | |
| 1+ | 294 (49.8) | 88 (34.1) | 206 (62.0) | <0.001 |
| Carcinoembryonic antigen (CEA), median (IQR) (ng/mL) | 430 patients, 62.2 (283.4) | 193 patients, 26.6 (146.3) | 237 patients, 121.4 (430.3) | |
| Hemoglobin, CTC grade | <0.001 | |||
| 0 | 356 (59.9) | 177 (68.1) | 179 (53.6) | |
| 1+ | 238 (40.1) | 83 (31.9) | 155 (46.4) | |
| Bilirubin, CTC grade | 0.015 | |||
| 0 | 556 (93.8) | 249 (96.5) | 307 (91.6) | |
| 1+ | 37 (6.2) | 9 (3.5) | 28 (8.4) |
*, P-value by ANOVA for continuous variables, etc., as described in methods. P-value excludes patients who did not survive 1 year and were censored.